Report Overview

The China Psoriasis Drugs market size stood at around USD 0.43 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Chinas psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2019-2028 forecast period. With the ongoing reforms in the regulatory and access and reimbursement landscape of China, multinational companies are likely to be increasingly incentivized to enter the Chinese psoriasis market.



Market Drivers

The Increase in rising healthcare expenditure, the introduction of novel and more advanced drugs, rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics. Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The high cost of psoriasis therapy is a restraint for the psoriasis market. Also, Combination therapy is an emerging trend in the psoriasis market.